Shi-dai Mu and Lisha Ai contributed equally to this work
Chunyan Sun and Yu Hu contributed equally to this work
Recent studies have emphasized the important prognostic role of long noncoding RNAs (lncRNAs) in various types of cancers. Here we conducted a meta-analysis to investigate whether lncRNA HOXA11-AS can be served as a prognostic biomarker in human cancers.
We systematically searched PubMed, Embase, ISI Web of Science, and SCOPUS for relevant studies, to investigate the prognostic significance of HOXA11-AS expression in cancer patients. Odds ratios (ORs) or hazards ratios (HRs) with corresponding 95% confidence intervals (CIs) are pooled to estimate the association between HOXA11-AS expression and clinicopathological parameters or survival of cancer patients.
A total of eight eligible studies with 1320 cancer patients were enrolled in our meta-analysis. The results revealed that increased expression level of HOXA11-AS was significantly associated with clinicopathological parameters including more lymph node metastasis (OR = 2.06, 95% CI 1.31–3.25), advanced tumor stage (OR = 4.22, 95% CI 2.60–6.85), as well as poor tumor differentiation (OR = 2.49, 95 CI 1.47–4.20), but not correlated with age (p = 0.101) or gender (p = 0.845). In addition, cancer patients with high HOXA11-AS are prognosed to have shorter OS (pooled HR = 1.86, 95% CI 1.39–2.48) and PFS (pooled HR = 2.47, 95% CI 1.29–4.75).
HOXA11-AS overexpression might be a convinced unfavorable prognostic factor that helps the clinical decision-making process.
Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochem Biophys Acta. 2014;1839(11):1097–109. PubMed
De Clara E, Gourvest M, Ma H, Vergez F, Tosolini M, Dejean S, Demur C, Delabesse E, Recher C, Touriol C et al. Long noncoding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. Haematologica. 2017;102(10):1718–26.
Kim HJ, Lee JY, Nam EJ, Park SA, Kim S, Kim SW, Kim YT. Upregulation of long noncoding RNA HOXA11 antisense promotes tumor progression and stemness maintenance of cervical cancer cells. Gynecol Oncol. 2016;141:75. CrossRef
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999;17(24):2815–34. CrossRef
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Hospital Research Institute; 2013. p. 1–4.
Stuck AE, Rubenstein LZ, Wieland D, Vandenbroucke JP, Irwig L, Macaskill P, Berry G, Glasziou P, Seagroatt V, Stratton I. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7129):629–34.
Sun M, Nie F, Wang Y, Zhang Z, Hou J, He D, Xie M, Xu L, De W, Wang Z, et al. LncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1. Can Res. 2016;76(21):6299–310. CrossRef
Wang X, Peng F, Cheng L, Yang G, Zhang D, Liu J, Chen X, Zhao S. Prognostic and clinicopathological role of long non-coding RNA UCA1 in various carcinomas. Mol Cancer. 2017;8(17):28373–84.
- Prognostic and clinicopathological significance of long noncoding RNA HOXA11-AS expression in human solid tumors: a meta-analysis
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II